Key result
Pazopanib treatment in a patient with intimal sarcoma of the pulmonary artery led to initial tumor shrinkage, but drug cessation due to hand-foot syndrome triggered a rapid disease flare.
Why the study?
Does pazopanib induce tumor regression in intimal sarcoma of the pulmonary artery?
Case Report (n=1)
No
Does pazopanib induce tumor regression in intimal sarcoma of the pulmonary artery?
Pazopanib may be an effective treatment for unresectable or recurrent intimal sarcoma of the pulmonary artery, though drug cessation can lead to disease flare.
Answers are grounded in this paper and cite their sources.
Supports pazopanib activity in pulmonary artery intimal sarcoma; leaves open durability and flare prevention.
Intimal sarcoma is a rare disease with a poor prognosis. We herein report the case of a 71-year-old man with intimal sarcoma of the pulmonary artery treated with pazopanib. The tumor showed regression after 1 month of treatment. Hand-foot syndrome led to cessation of pazopanib, which triggered a disease flare. Pazopanib should be considered in patients with intimal sarcoma of the pulmonary artery that is unresectable or recurrent after surgery or cytotoxic chemotherapy. We must be careful about drug cessation, as it can lead to a disease flare.
No takes yet. Share an insight, caveat, or question.
Funatsu et al. (2016) conducted a case report in Intimal sarcoma of the pulmonary artery (n=1). Pazopanib was evaluated. Pazopanib treatment in a patient with intimal sarcoma of the pulmonary artery led to initial tumor shrinkage, but drug cessation due to hand-foot syndrome triggered a rapid disease flare.
Synapse has enriched 10 related papers. Consider them for comparative context: